The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.
about
Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic TargetTargeting the insulin-like growth factor pathway in hepatocellular carcinomaRole of innate immunity in the development of hepatocellular carcinomaPeptides as targeting probes against tumor vasculature for diagnosis and drug deliveryThe altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transportersPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesTherapeutic potential of the translation inhibitor silvestrol in hepatocellular cancerInflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular CarcinomaImpact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinomaIntegrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma markerTGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCCIdentification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®.Macro- and micro-environmental factors in clinical hepatocellular cancer.Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.Downregulation of UHRF1 increases tumor malignancy by activating the CXCR4/AKT-JNK/IL-6/Snail signaling axis in hepatocellular carcinoma cells.Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior.Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigationsSoluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma.Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation.Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice.Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells.Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell linesGRP78 and GAL3, differentially regulated by lymph node homogenates, as potential biomarkers for lymph node metastasis in mouse hepatocellular carcinoma cellsMolecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma.Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patientsBeta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells.A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinomaIntratumoral hepatic stellate cells as a poor prognostic marker and a new treatment target for hepatocellular carcinoma.Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis.Matrix metalloproteinase-7 mRNA and protein expression in gastric carcinoma: a meta-analysis.Epithelial-Mesenchymal Transition in tumor microenvironment.Regulator of G-protein signaling-5 is a marker of hepatic stellate cells and expression mediates response to liver injuryGenes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profilingDown-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma.
P2860
Q26797288-C10A010D-BFE2-4020-B95F-2BC834046B58Q27006846-69FF0006-1C88-40A7-8BC1-1F305A95A1FDQ27024780-9C78A928-520C-44CB-B4FF-F01EC4712664Q27024850-9EAF9F6D-56D9-414E-A811-198E595C6837Q28072360-568B1510-8C11-4414-B1C5-93A4346DA2EDQ28272678-B5BCB8F6-DD66-4B21-A3AE-EA11AA0FB7D7Q28533823-E3BF2F4E-49B6-4FFD-B74D-8B17A0C2E14AQ28550411-FEF0F2C4-DD94-404C-B27F-0A58D1A919B8Q28730441-ECCE0962-2B34-4923-9EC3-A834EF84510FQ30834745-EBD3E5A7-ACD5-427B-B47E-BD9E7F4A927DQ31113966-13E49004-9696-4486-BF64-0682005A86D1Q33591632-E187C2EA-A36C-4BE4-B5B1-B8815A3734CBQ33595736-922E2722-FEF7-4822-A23D-4AD9A8290822Q33600604-893B2FAC-A571-41F0-8332-30967BB214A9Q33713444-CC35C3E5-E0ED-4045-A21C-5B472F984733Q33765984-5355BD3D-A25A-4F05-A70C-17CEF79A0D25Q34050895-C111A913-2B44-45F9-8B2D-28334AD48B02Q34134852-BC0A0DD6-E5CA-4D74-B759-76818A298ACFQ34277756-EF600B6B-EF9E-46BD-9326-25F7FC961BEAQ34355442-6A263B15-509C-4787-A697-6BEC5211C211Q34359125-74EBDC69-8878-4B56-9702-18AC6230F4F5Q34399693-37665B58-DEAA-4124-BB9E-5D9AC49380FEQ34410337-8DF97FDD-5015-4CFE-A8AF-237F174DCC53Q34498142-AC740E8A-9B18-4071-8580-8B9B06A9EE00Q34521354-555A8537-3EA4-4326-9994-5FD9F5B85329Q34589814-694DEC3B-B3A2-4E3C-AD33-CAE667E5645AQ34630557-B1381BCE-91F2-4E46-A61D-9C01DD04B14DQ34704882-F287667C-A268-43B3-90AF-B927F068E043Q34769755-03799B68-4A88-4729-8214-E81770A7A145Q34984377-D0A7FA94-DAAA-49F5-9C25-D371C198113BQ35053501-D28E0959-5CE1-4978-BB66-4967D0776CBBQ35111392-FC4112BA-7847-4507-ABB9-DC78B7F9F96AQ35141906-7E60B42A-2085-4A4A-A4E4-E946AD80FF84Q35212827-21300221-114A-4110-92E8-5D0963051F79Q35225047-56496570-44D7-43F2-93E2-55D136DC53BBQ35230386-1C29E2C4-6D24-42A8-A33F-2F970623515EQ35309176-F78DD612-DC44-4232-B7E5-0D3549DD6907Q35511482-6B264458-6E67-4539-879F-7C5A81263704Q35632482-179BC158-6ED2-44B0-82AD-372D69060930Q35684366-84454071-6DA0-4CE1-8EC1-BEEA941AEADE
P2860
The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The tumor microenvironment in ...... tatus and therapeutic targets.
@en
The tumor microenvironment in ...... tatus and therapeutic targets.
@nl
type
label
The tumor microenvironment in ...... tatus and therapeutic targets.
@en
The tumor microenvironment in ...... tatus and therapeutic targets.
@nl
prefLabel
The tumor microenvironment in ...... tatus and therapeutic targets.
@en
The tumor microenvironment in ...... tatus and therapeutic targets.
@nl
P2860
P1476
The tumor microenvironment in ...... status and therapeutic targets
@en
P2093
Ikuo Nakamura
Ju Dong Yang
P2860
P356
10.1016/J.SEMCANCER.2010.10.007
P577
2010-10-12T00:00:00Z